Search over 3,000 reports

    Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023

    Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 88
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0008
    Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.
    DelveInsight's "Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023. According to DelveInsight, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.
    As per DelveInsight's estimation, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
    - Marketed information including available prescription drugs.
    - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
    - It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
    Report Introduction
    Acne Vulgaris Market Overview at a Glance
    Total Market Size of Acne Vulgaris for 7 MM in 2010-2023
    Total Market Share Distribution of Acne Vulgaris for 7 MM in 2015
    Total Market Share Distribution of Acne Vulgaris for 7 MM in 2023
    Acne Vulgaris
    Overview
    Signs and symptoms
    Types of Acne
    Pathophysiology
    Diagnosis
    Epidemiology and Patient Population
    United States
    Diagnosed Cases of Acne Vulgaris in United States
    Germany
    Diagnosed Cases of Acne Vulgaris in Germany
    France
    Diagnosed Cases of Acne Vulgaris in France
    United Kingdom
    Diagnosed Cases of Acne Vulgaris in United Kingdom
    Spain
    Diagnosed Cases of Acne Vulgaris in Spain
    Italy
    Diagnosed Cases of Acne Vulgaris in Italy
    Japan
    Diagnosed Cases of Acne Vulgaris in Japan
    Treatment Algorithm
    Marketed Drugs
    Top Marketed Drugs for Acne Vulgaris
    Acanya: Valeant Pharmaceuticals
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Acanya
    Product Profile
    Tazorac: Allergan
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Tazorac
    Product Profile
    Veltin: Almirall, S.A.
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Product Profile
    Duac: Glaxosmithkline
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Product Profile
    Epiduo and Epiduo Forte: Galderma S.A.
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Epiduo
    Product Profile
    Emerging Therapies
    Major Pipeline drugs
    Sarecycline: Paratek Pharmaceuticals
    Regulatory Milestones
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Aczone reform: Allergan
    Advantages & Disadvantages
    Product Profile
    SB204: Novan, Inc.
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Global Acne Vulgaris: Country-Wise Market Analysis
    Overview on Total Acne Vulgaris Market (2015)
    Overview on Total Acne Vulgaris Market (2023)
    United States Market Size
    Europe Market Size
    United Kingdom Market Size
    Germany Market Size
    France Market Size
    Italy Market Size
    Spain Market Size
    Japan Market Size
    Market Drivers
    Market Restraints
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Diagnosed Cases Acne Vulgaris in United States (2013-2023)
    Table 2: Diagnosed Cases Acne Vulgaris in Germany (2013-2023)
    Table 3: Diagnosed Cases Acne Vulgaris in France (2013-2023)
    Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2013-2023)
    Table 5: Diagnosed Cases Acne Vulgaris in Spain (2013-2023)
    Table 6: Diagnosed Cases Acne Vulgaris in Italy (2013-2023)
    Table 7: Diagnosed Cases Acne Vulgaris in Japan (2013-2023)
    Table 8: List of Marketed Drugs for Acne Vulgaris
    Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris
    Table 10: Sarecycline, Clinical Trials by Zone, 2016
    Table 11: Clinical Trials by Trial status, 2016
    Table 12: SB204, Clinical Trials by Zone, 2016
    Table 13: Clinical Trials by Trial status, 2016
    Table 14: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 15: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 16: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 17: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 18: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 19: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Table 20: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 1: Cellular mechanisms hypothesized to govern the pathogenesis of Acne Vulgaris
    Figure 2: Diagnosed Cases of Acne Vulgaris in United States (2013-2023)
    Figure 3: Diagnosed Cases of Acne Vulgaris in Germany (2013-2023)
    Figure 4: Diagnosed Cases of Acne Vulgaris in France (2013-2023)
    Figure 5: Diagnosed Cases of Acne Vulgaris in United Kingdom (2013-2023)
    Figure 6: Diagnosed Cases of Acne Vulgaris in Spain (2013-2023)
    Figure 7: Diagnosed Cases of Acne Vulgaris in Italy (2013-2023)
    Figure 8: Diagnosed Cases of Acne Vulgaris in Japan (2013-2023)
    Figure 9: Sarecycline, Clinical Trials by Zone (%), 2016
    Figure 10: Sarecycline, Clinical Trials by Trial status (%), 2016
    Figure 11: SB204, Clinical Trials by Zone (%), 2016
    Figure 12: SB204, Clinical Trials by Trial status (%), 2016
    Figure 13: Total Market Size of Acne Vulgaris in USD, Million (2015)
    Figure 14: Total Market Size of Acne Vulgaris in USD, Million (2023)
    Figure 15: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 16: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 18: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 19: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Figure 21: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)
    Acne Vulgaris (AV) Market (7MM)

    Acne Vulgaris (AV) Market forecasting

    Acne Vulgaris (AV) Sales forecasting

    Acne Vulgaris (AV) Market segments

    Acne Vulgaris (AV) Epidemiology

    Acne Vulgaris (AV) Pipeline products and technologies

    Acne Vulgaris (AV) Competitive landscape

    Acne Vulgaris (AV) SWOT analysis

    Acne Vulgaris (AV) Market Driver's and barriers

    Acne Vulgaris (AV) Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap